

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**FOSUN 复星**  
**復星國際有限公司**  
**FOSUN INTERNATIONAL LIMITED**  
*(Incorporated in Hong Kong with limited liability)*  
**(Stock Code: 00656)**

**PROFIT WARNING**

This announcement is made by the board (the “**Board**”) of directors of Fosun International Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company and potential investors that based on the information available to the Company and the latest unaudited consolidated management accounts for the year ended 31 December 2025 (the “**2025 Financial Year**”), the loss attributable to owners of the parent of the Company for the 2025 Financial Year is expected to be approximately RMB21.5 billion to RMB23.5 billion (2024: a loss of approximately RMB4.35 billion). Pursuant to the principle of financial prudence, the Company has made one-off non-cash impairment provisions and value revaluations on certain assets, which is the primary reason for the significant book loss in the 2025 financial statements. The details are as follows:

1. During the 2025 Financial Year, the real estate industry has continued in a downward cycle with overall weak market demand, exerting pressure on the Group’s real estate business segment. In accordance with the principle of prudence, the Company has made substantial asset impairment provisions for certain real estate projects with impairment indicators. The Group will dynamically adjust its operating and sales strategies in light of market conditions, actively seize opportunities, step up efforts in marketing and inventory clearance, and accelerate cash recovery.
2. Due to changes in market conditions, the Company has made impairment provisions on goodwill and intangible assets of certain non-core business segments to objectively reflect their value.

The Board is of the view that the above-mentioned substantial non-cash impairments and provision made on assets are intended to reflect the Company’s financial information faithfully,

and will not affect the overall operations and cash flows of the Company. The Company's fundamentals remain stable and core industries such as pharmaceuticals and healthcare and insurance and finance have shown a good development trend. The Company will continue its corporate strategy of focusing on core principal businesses and financial strategy of streamlining operations and strengthening the business. The Company will drive business growth through refined operations, consolidate the Company's long-term value, and create sustainable and stable returns for shareholders.

The Company is in the process of preparing for and finalizing the Group's results for the 2025 Financial Year. The information contained in this announcement is based solely on the Group's unaudited consolidated management accounts for the 2025 Financial Year and the information available as at the date of this announcement, and has not been audited by the Company's independent external auditors nor reviewed and approved by the audit committee of the Board. The above estimates may therefore be different from the audited consolidated annual results of the Group for the 2025 Financial Year. The Company will publish the audited annual results of the Company for the 2025 Financial Year in compliance with the requirements of the Listing Rules.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Fosun International Limited**  
**Guo Guangchang**  
*Chairman*

6 March 2026

*As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Huang Zhen and Mr. Pan Donghui; the non-executive directors are Mr. Li Fuhua and Mr. Luo Yuanli; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Dr. Lee Kai-Fu and Ms. Tsang King Suen Katherine.*